MX2021000998A - Oligonucleotidos antisentido de acetil-coa carboxilasa2. - Google Patents

Oligonucleotidos antisentido de acetil-coa carboxilasa2.

Info

Publication number
MX2021000998A
MX2021000998A MX2021000998A MX2021000998A MX2021000998A MX 2021000998 A MX2021000998 A MX 2021000998A MX 2021000998 A MX2021000998 A MX 2021000998A MX 2021000998 A MX2021000998 A MX 2021000998A MX 2021000998 A MX2021000998 A MX 2021000998A
Authority
MX
Mexico
Prior art keywords
coa
acetyl
antisense oligonucleotides
human acc2
mrna
Prior art date
Application number
MX2021000998A
Other languages
English (en)
Inventor
Seon-Young Han
Kiho Sung
Myunghyo Hong
Jeong-Seok Heo
Kang Won Jang
Dayoung Kang
Original Assignee
Olipass Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olipass Corp filed Critical Olipass Corp
Publication of MX2021000998A publication Critical patent/MX2021000998A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y604/00—Ligases forming carbon-carbon bonds (6.4)
    • C12Y604/01—Ligases forming carbon-carbon bonds (6.4.1)
    • C12Y604/01002—Acetyl-CoA carboxylase (6.4.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona el derivado de ácido nucleico peptídico que se dirige al sitio de corte y empalme 5' del "exón 12" humano de ACC2. Los derivados de ácido nucleico peptídico en la presente invención inducen en gran medida variantes de empalme del ARNm de ACC2 humano en la célula y son muy útiles para tratar afecciones o trastornos del envejecimiento de la piel asociados con la proteína ACC2 humana.
MX2021000998A 2018-08-14 2019-08-05 Oligonucleotidos antisentido de acetil-coa carboxilasa2. MX2021000998A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180095124A KR102304280B1 (ko) 2018-08-14 2018-08-14 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드
PCT/KR2019/009697 WO2020036353A1 (en) 2018-08-14 2019-08-05 Acetyl-coa carboxylase2 antisense oligonucleotides

Publications (1)

Publication Number Publication Date
MX2021000998A true MX2021000998A (es) 2021-06-23

Family

ID=69525636

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000998A MX2021000998A (es) 2018-08-14 2019-08-05 Oligonucleotidos antisentido de acetil-coa carboxilasa2.

Country Status (13)

Country Link
US (1) US11739124B2 (es)
EP (1) EP3837274A4 (es)
JP (2) JP2021534146A (es)
KR (1) KR102304280B1 (es)
CN (1) CN112566922B (es)
AR (1) AR115955A1 (es)
AU (1) AU2019320670B2 (es)
BR (1) BR112020026541A2 (es)
CA (1) CA3104658A1 (es)
MX (1) MX2021000998A (es)
SG (1) SG11202012829RA (es)
TW (1) TWI826490B (es)
WO (1) WO2020036353A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304280B1 (ko) 2018-08-14 2021-09-23 올리패스 주식회사 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133444A (en) 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
US6617422B1 (en) 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US20030105044A1 (en) 2001-10-17 2003-06-05 Isis Pharmaceuticals Inc. Antisense modulation of matrix metalloproteinase 1 expression
US20040215006A1 (en) 2003-04-25 2004-10-28 Isis Pharmaceuticals Inc. Modulation of tyrosinase expression
GB0415196D0 (en) * 2004-07-07 2004-08-11 Astrazeneca Ab Polypeptide
US7211423B2 (en) * 2004-07-23 2007-05-01 Bristol-Myers Squibb Co. Acetyl CoA carboxylase 2 sequences and methods
AU2006235451A1 (en) * 2005-04-08 2006-10-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to acetyl-CoA carboxylases
BE1017127A6 (nl) 2006-03-24 2008-03-04 Hyfte Luc J R Van Scharnierende bevestiging van een paddelroerwerk.
JP2010075639A (ja) * 2007-10-19 2010-04-08 Shiseido Co Ltd 顔面及び頸部の皮膚状態を改善する美容方法及び装置
KR20090098710A (ko) 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
KR20110112381A (ko) 2008-12-31 2011-10-12 레반스 테라퓨틱스, 아이엔씨. 색소 과다 침착의 치료용 조성물 및 치료 방법
WO2010123983A1 (en) 2009-04-21 2010-10-28 Yale University Compostions and methods for targeted gene therapy
KR20120073536A (ko) * 2010-12-27 2012-07-05 주식회사 파나진 다중전하를 갖는 ｐｎａ
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
US20140314697A1 (en) 2013-04-18 2014-10-23 Corum Inc. Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof
KR101809209B1 (ko) * 2016-05-31 2017-12-15 주식회사 올리패스코스메슈티컬즈 두피의 건강 개선을 위한 화장료 조성물 및 이의 제조방법
US20190345202A1 (en) * 2016-08-08 2019-11-14 Olipass Corporation Androgen receptor antisense oligonucleotides
EP3512870B1 (en) 2016-09-16 2022-08-03 Olipass Corporation Scn9a antisense oligonucleotides
RU2753517C2 (ru) 2016-10-11 2021-08-17 Олипасс Корпорейшн Антисмысловые олигонуклеотиды к hif-1-альфа
US20190337987A1 (en) * 2016-12-30 2019-11-07 Olipass Corporation Exon skipping by peptide nucleic acid derivatives
JP7503903B2 (ja) * 2017-01-06 2024-06-21 オリパス コーポレーション Ｓｎａｐ２５アンチセンスオリゴヌクレオチド
RU2762293C2 (ru) 2017-01-24 2021-12-17 Олипасс Корпорейшн Антисмысловое для scn9a обезболивающее средство
WO2019022434A1 (en) 2017-07-24 2019-01-31 Olipass Corporation ANTISENSE OLIGONUCLEOTIDES OF TYROSINASE
TWI832851B (zh) 2018-05-18 2024-02-21 韓商奧利通公司 基質金屬蛋白酶-1之反義寡核苷酸
KR102304280B1 (ko) 2018-08-14 2021-09-23 올리패스 주식회사 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드
JP2022541896A (ja) 2019-07-18 2022-09-28 オリパス コーポレーション メラノフィリンアンチセンスオリゴヌクレオチド

Also Published As

Publication number Publication date
AU2019320670A1 (en) 2021-02-11
US11739124B2 (en) 2023-08-29
WO2020036353A1 (en) 2020-02-20
EP3837274A1 (en) 2021-06-23
TW202022115A (zh) 2020-06-16
CN112566922A (zh) 2021-03-26
EP3837274A4 (en) 2022-05-18
CN112566922B (zh) 2024-09-13
JP2021534146A (ja) 2021-12-09
AU2019320670B2 (en) 2024-04-11
KR102304280B1 (ko) 2021-09-23
KR20200019509A (ko) 2020-02-24
TWI826490B (zh) 2023-12-21
AR115955A1 (es) 2021-03-17
SG11202012829RA (en) 2021-02-25
JP2024038106A (ja) 2024-03-19
US20210363190A1 (en) 2021-11-25
BR112020026541A2 (pt) 2021-04-06
CA3104658A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
NZ747685A (en) Oligonucleotide analogues targeting human lmna
BR112017016068A2 (pt) composições para modulação de expressão de c9orf72
EP3700570A4 (en) ANTISENSE OLIGOMERS FOR THE TREATMENT OF CONDITIONS AND DISEASES BASED ON THE DECLINE OF NON-SENSE MEDIATION RNA
EP4166667A3 (en) Compositions for modulating c9orf72 expression
PH12017550069A1 (en) Tau antisense oligomers and uses thereof
EP3862362A3 (en) Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.
MX2019008445A (es) Calmante de dolor scn9a antisentido.
BR112022002691A2 (pt) Construtos de vesícula-aso extracelular visando stat6
BR112019002387A2 (pt) oligonucleotídeos antissenso de receptor de andrógeno
WO2011090741A3 (en) TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
AR107579A1 (es) Composiciones y métodos para disminuir la expresión de tau
MX2020007439A (es) Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos.
SA520412423B1 (ar) أوليجونيوكليوتيدات مضادة للحس تستهدف ألفا- سينيوكلين واستخداماتها
WO2017151860A8 (en) Human kynureninase enzyme variants having improved pharmacological properties
MX2021000998A (es) Oligonucleotidos antisentido de acetil-coa carboxilasa2.
Zhu et al. Regulation of acetylcholinesterase expression by calcium signaling during calcium ionophore A23187-and thapsigargin-induced apoptosis
EA201792406A1 (ru) Антисмысловые олигонуклеотиды для лечения дистрофического буллезного эпидермолиза
MX2020009836A (es) Oligonucleotidos antisentido de metaloproteinasa-1 de matriz.
MX2023009151A (es) Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina.
MX2019007903A (es) Oligonucleotidos antisentido de proteina asociada a sinaptosoma de 25 kda (snap25).
MX2020008533A (es) Terapia con oligonucleotidos para la enfermedad de wilson.
Davidson et al. A5. 18 BMP2 requires TGF-BETA to induce osteophytes during experimental osteoarthritis
Gauthier-Rouvière et al. RhoA leads to up-regulation and relocalization of utrophin in muscle fibers